ABCG2 and osteosarcoma: Our prospective pharmacogenetic study conducted in patients diagnosed with non-metastatic high-grade osteosarcoma of the extremities and treated with neoadjuvant MAP chemotherapy shows variants in ABC transporter genes that may identify patients with poor response and patients at risk of hepatic toxicity at diagnosis.